Colfosceril Palmitate
drugOn this page
Also known as 129Y83ColfoscerilDipalmitoyl glycerophosphocholineDipalmitoyl lecithinl-DipalmitoylphosphatidylcholineDppcr-Palmitate de colfoscerilPalmitato de colfosceriloSID8139918SID144206116COLFOSCERIL-PALMITATE
Summary
Colfosceril Palmitate (CHEMBL1200737) is an approved small-molecule surfactant (ATC R07AA01); indicated across 2 conditions including respiratory system disorder and newborn respiratory distress syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: R07AA01
- Indications: 2 conditions
- Chemistry: 734 Da · C40H80NO8P
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200737 |
| Name | Colfosceril Palmitate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 452110 |
| ChEBI | CHEBI:72999 |
| ATC | R07AA01 |
| Molecular formula | C40H80NO8P |
| Molecular weight | 734 |
| InChIKey | KILNVBDSWZSGLL-KXQOOQHDSA-N |
SMILES: CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
IUPAC name: [(2R)-2,3-di(hexadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
ChEBI definition: A phosphatidylcholine 32:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl). A synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of pulmonary surfactants.
Pharmacological roles (ChEBI): surfactant.
Other ChEBI roles (chemical / environmental): mouse metabolite.
Also known as: 129Y83, Colfosceril, Colfosceril palmitate, Dipalmitoyl glycerophosphocholine, Dipalmitoyl lecithin, l-, Dipalmitoylphosphatidylcholine, Dppc, r-, Palmitate de colfosceril, Palmitato de colfoscerilo, SID8139918
Patent coverage: 6,290 distinct patent families (16,167 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Survival motor neuron protein, Beta-lactamase.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P00811 | 6.45 | Potency | 354.8 | nM | CHEMBL_ACT_4742811 |
| SMN1 | 5.75 | Potency | 1778 | nM | CHEMBL_ACT_3862355 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| respiratory system disorder | 4 | MONDO:0005087 | EFO:0000684 |
| newborn respiratory distress syndrome | 4 | MONDO:0700081 | EFO:1000644 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).